These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

556 related items for PubMed ID: 22566747

  • 1. Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis.
    Gaebler JA, Soto-Campos G, Alperin P, Cohen M, Blickensderfer A, Wintle M, Maggs D, Hoogwerf B, Han J, Pencek R, Peskin B.
    Vasc Health Risk Manag; 2012; 8():255-64. PubMed ID: 22566747
    [Abstract] [Full Text] [Related]

  • 2. Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.
    Guillermin AL, Lloyd A, Best JH, DeYoung MB, Samyshkin Y, Gaebler JA.
    J Med Econ; 2012; 15(4):654-63. PubMed ID: 22369345
    [Abstract] [Full Text] [Related]

  • 3. Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US.
    Samyshkin Y, Guillermin AL, Best JH, Brunell SC, Lloyd A.
    J Med Econ; 2012; 15 Suppl 2():6-13. PubMed ID: 22793669
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
    Gu S, Wang X, Qiao Q, Gao W, Wang J, Dong H.
    Diabetes Obes Metab; 2017 Dec; 19(12):1688-1697. PubMed ID: 28452095
    [Abstract] [Full Text] [Related]

  • 8. Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece.
    Tzanetakos C, Bargiota A, Kourlaba G, Gourzoulidis G, Maniadakis N.
    Clin Drug Investig; 2018 Jan; 38(1):67-77. PubMed ID: 29080210
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.
    Lee WC, Conner C, Hammer M.
    Clin Ther; 2010 Sep; 32(10):1756-67. PubMed ID: 21194600
    [Abstract] [Full Text] [Related]

  • 12. A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo.
    Scott DA, Boye KS, Timlin L, Clark JF, Best JH.
    Diabetes Obes Metab; 2013 Mar; 15(3):213-23. PubMed ID: 22958381
    [Abstract] [Full Text] [Related]

  • 13. Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.
    Ryan GJ, Moniri NH, Smiley DD.
    Am J Health Syst Pharm; 2013 Jul 01; 70(13):1123-31. PubMed ID: 23784159
    [Abstract] [Full Text] [Related]

  • 14. Real-world clinical outcomes and predictors of glycaemic and weight response to exenatide once weekly in patients with type 2 diabetes: The CIBELES project.
    Gorgojo-Martínez JJ, Gargallo-Fernández MA, Brito-Sanfiel M, Lisbona-Catalán A.
    Int J Clin Pract; 2018 Mar 01; 72(3):e13055. PubMed ID: 29341370
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.
    Ridge T, Moretto T, MacConell L, Pencek R, Han J, Schulteis C, Porter L.
    Diabetes Obes Metab; 2012 Dec 01; 14(12):1097-103. PubMed ID: 22734440
    [Abstract] [Full Text] [Related]

  • 17. Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.
    Meloni AR, DeYoung MB, Han J, Best JH, Grimm M.
    Cardiovasc Diabetol; 2013 Mar 23; 12():48. PubMed ID: 23522121
    [Abstract] [Full Text] [Related]

  • 18. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.
    Wysham C, Bergenstal R, Malloy J, Yan P, Walsh B, Malone J, Taylor K.
    Diabet Med; 2011 Jun 23; 28(6):705-14. PubMed ID: 21434995
    [Abstract] [Full Text] [Related]

  • 19. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
    Blevins T, Pullman J, Malloy J, Yan P, Taylor K, Schulteis C, Trautmann M, Porter L.
    J Clin Endocrinol Metab; 2011 May 23; 96(5):1301-10. PubMed ID: 21307137
    [Abstract] [Full Text] [Related]

  • 20. Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study.
    Simó R, Guerci B, Schernthaner G, Gallwitz B, Rosas-Guzmàn J, Dotta F, Festa A, Zhou M, Kiljański J.
    Cardiovasc Diabetol; 2015 Sep 04; 14():116. PubMed ID: 26338040
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.